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Response to: Systematic review:
animal studies of TB vaccines
From Ann Williams1, Sally Sharpe1, Frank Verreck2, Martin Vordermeier3 and Glyn Hewinson3
1Public Health England, National Infections Service, Manor Farm Road, Porton, Salisbury, SP4 0JG, 2Biomedical Primate
Research Centre, Department of Parasitology, Rijswijk, The Netherlands and 3Animal and Plant Health Agency,
Department of Bacteriology, Weybridge, UK
We write in response to the article by Kashangura et al.,1
published on 8 September 2015, entitled ‘Effects of
MVA85A vaccine on tuberculosis challenge in animals:
systematic review’, in which the published efficacy data
generated in our respective animal models on the TB candi-
date vaccine, MVA85A, were reviewed. This review is fact-
ually incorrect and, consequently, is potentially harmful to
the process of vaccine development in a field where an
effective vaccine is so urgently needed and where know-
ledge gaps hamper the swift and rationalized implementa-
tion of an improved vaccine strategy.
• An overarching theme of the review is that the animal
studies were of poor quality. All institutes involved in
the studies are in compliance with national laws and
international directives; all studies were subject to in-
dependent ethical review before starting and, on sub-
mission for publication, were evaluated for ethical
rigour by reviewers and editorial boards of independ-
ent journals. The review states that there was no ran-
domization, baseline comparability was not
described and blinding was not reported—these are
standard requirements for obtaining ethical permis-
sion and the authors cannot justify claims that they
were lacking from the experiments purely on the
basis that it was not reported in the original
publication.
• The language used in the review reflects emotive ra-
ther than scientific writing. To refer to animal
‘death’ is entirely incorrect and unwarranted, as hu-
mane endpoint criteria and euthanasia of animals
were in place. The same applies to the term ‘severe
morbidity’. This misuse of terminology reflects a
poor knowledge of animal experimentation and, in
particular, of TB animal models. As far as the bovine
infection model is concerned, it is designed as a
preclinical, asymptomatic infection model that does
not lead to clinical signs of bovine TB. This is re-
flected in the strictly defined endpoints, which in
practice have never been reached. Thus the model is
classified in the UK licensing scheme at the lowest
level. It is unjustified and entirely incorrect, there-
fore, for the review by Kashangura et al.1 to give the
impression that animal suffering had occurred.
• The authors persistently refer to animal trials, but
many of the studies were exploratory by nature and
not efficacy trials of vaccine candidates. In particular,
the non-human primate (NHP) and the cattle study
designs were the first of their kind and were con-
ducted in order to generate data which could be used
to determine variability in effect size and to perform
power calculations for subsequent studies.The guinea
pig studies were conducted more than a decade ago
and, as concluded by Williams et al.,2 progression to
humane endpoint as a primary measure of efficacy
was subsequently shown not to be useful to discrim-
inate small differences between test groups, particu-
larly to demonstrate efficacy better than BCG.
Accordingly, head-to-head testing of vaccines in the
guinea pig model now employs an early, fixed
endpoint of bacterial load in organs, which has high
statistical and discriminative power.
• The authors have selected and extracted lung path-
ology or bacterial load data to perform their own
analyses. There are several reasons why it is inappro-
priate to do this which include (but are not limited
to) important differences in disease progression be-
tween the animal species, the dose, species and strain
of Mycobacterium used and the time post-challenge
that the measurements were made. The authors have
completely overlooked the fact that several of these
studies were designed to understand the impact of
vaccines on the complex disease profile and were not
a simple colony-forming unit (CFU) comparison be-
tween different treatment groups.
• All but one of the papers were published before the
MVA85A clinical trial started, a fact which does not
support the authors’ final conclusion in the Abstract:
‘We believe the results of the studies should be pub-
licly available before embarking on trials in humans,
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irrespective of the findings’. We also support such an
open approach, and this is exemplified by the large
number of publications (many of which are listed in,
and the subject of the review) where we report our
findings on MVA85A, and several other vaccine can-
didates which have progressed to clinical trials.
Despite it being explicitly highlighted in the original
publication, Kashangura et al.1 have failed to under-
stand that the study which they consider to have
been delayed was explorative and designed to assess
a new infection strategy by using the aerosol chal-
lenge route. Such a study does not end when the
in vivo phase is finished. The work was published
after careful analysis of all parameters without any
delay whatsoever.The statement that the results were
published ‘ ... 2 years after this trial in monkeys had
been completed’ is curious since no dates were speci-
fied in the Sharpe et al.3 publication which could
allow this (erroneous) conclusion of deliberate delay
to be made. Further, the cattle study referred to in
this review was not conducted as a preclinical study
for human TB vaccination but was aimed at the de-
velopment of a cattle vaccine against bovine TB and
the focus of the paper was on biomarker discovery.
Any suggestion that this study was conducted as a
preclinical study to support any human field trial is
therefore without foundation.
In conclusion, our experiments have not only been mis-
interpreted but also portrayed as an isolated programme of
work focused on the development of a single candidate.
This is a gross misrepresentation of our efforts and the
goals of the entire human TB vaccine field, which were
(and still are) to pursue multiple vaccine candidates from
preclinical models through to clinical efficacy trials, with
the aim to identify an effective vaccine for humans and to
subsequently define the predictive validity of the animal
models.
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We thank the authors of the letters for their interest in our
systematic review of MVA85A vaccine on TB challenge in
animals.1
Professor Helen McShane and colleagues point out that
all trial-related decisions, including those made by ethics
committees and regulators, were taken after consideration
of all existing data from humans and animals, whether
published or unpublished.2 This is of course appropriate. It
might be argued, with the benefit of hindsight, that greater
emphasis might have been given, in the considerations by
all of these parties, to signals in the animal data relating to
progression of pathology and euthanasia endpoints, as
summarized in our review. We believe that an important
learning point from this experience is that independently
conducted systematic review and meta-analysis of relevant
animal data play an important role in such scientific, regu-
latory and ethical decisions for clinical trials in the future.
Dr Ann Williams and colleagues make a number of
comments.3 To reiterate, our purpose was: to summarize
the reported study quality; to summarize results across the
various outcomes reported; and to provide some insight
into why the human trial was not successful. We did this
using standard synthesis approaches in animal challenge
studies. Dr Williams and colleagues challenge our
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